The pharmacokinetics of midazolam in paediatric patients

Eur J Clin Pharmacol. 1989;37(3):267-72. doi: 10.1007/BF00679782.

Abstract

A serum concentration profile study on midazolam in children was done. Fifty six children aged 3-10 years took part. The routes investigated were intravenous, intramuscular, rectal and oral at 0.15 mg.kg-1, and the oral at 0.45 mg.kg-1 and 1 mg.kg-1. Serum concentration levels for 5 h were studied using gas liquid chromatography. The volume of distribution, Vss, was 1.29 l.kg-1, the elimination half-life 1.17 h and the serum clearance 9.11 ml.kg-1.min-1. Peak serum concentrations for the intramuscular, rectal and oral routes were at 15 min, 30 min and 53 min respectively. Bioavailability was 87%, 18%, 27% respectively at a dose of 0.15 mg.kg-1. The oral route bioavailability halved to 15% at the two higher doses. Bioequivalence was present between the 0.15 mg.kg-1 intramuscular dose and the 0.45 mg.kg-1 oral dose from 45 to 120 min.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Administration, Rectal
  • Child
  • Child, Preschool
  • Drug Interactions
  • Female
  • Half-Life
  • Humans
  • Infant
  • Injections, Intramuscular
  • Injections, Intravenous
  • Magnesium / pharmacology
  • Magnesium Silicates*
  • Male
  • Midazolam / administration & dosage
  • Midazolam / pharmacokinetics*
  • Silicic Acid / pharmacology
  • Therapeutic Equivalency

Substances

  • Magnesium Silicates
  • Silicic Acid
  • magnesium trisilicate
  • Magnesium
  • Midazolam